$APTOF News

Aptose Biosciences Inc. (APS:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC

Reported Saturday, Aptose Tuspetinib TUS+VEN+AZA Triplet Shows High Rates Of Efficacy And MRD-Negative Remissions In Newly Diagnosed AML Patients

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical

Aptose Biosciences: Q3 Earnings Snapshot

Aptose Reports Third Quarter 2025 Results

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

Aptose Biosciences Reports Promising Early Results from Tuscany AML Trial of Tuspetinib Combo Therapy

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

Aptose Secures US$11.9M Loan Extension to Advance Tuspetinib AML Trial

Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML

Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor

Aptose Biosciences Reports Early Positive Tuspetinib Safety Data Across Newly Diagnosed AML Patients

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

Aptose Biosciences: Q2 Earnings Snapshot

Aptose Reports Second Quarter 2025 Results

Aptose Biosciences Moves to Higher Dose in Phase 1/2 Cancer Study After Positive Safety Review

Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders